Mylan Says Amendment Feedback Doesn't Save Sanofi IP
Mylan urged the Patent Trial and Appeal Board on Wednesday to reject Sanofi-Aventis' substitute claims to insulin pen patents that were the first to pass through a new program that provides early...To view the full article, register now.
Already a subscriber? Click here to view full article